First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Charlotta Löfberg(Kancera (Sweden)), Amir Hossein Daneshmanesh(Karolinska University Hospital), Charlotta Carina Norström(Kancera (Sweden)), Lotta Hansson(Karolinska Institutet), Jan Vågberg(Kancera (Sweden)), Fariba Mozaffari(Karolinska University Hospital), Elisabeth Olsson(Karolinska Institutet), Styrbjörn Byström(Karolinska Institutet), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), Thomas Olin(Kancera (Sweden))
Cited by 1
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312